Last reviewed · How we verify
Kagocel
Kagocel is a Small molecule drug developed by Nearmedic Plus LLC. It is currently in Phase 2 development.
Kagocel is used to treat Influenza, Acute Upper Respiratory Infection, Acute Upper Respiratory Tract Infection, Respiratory Viral Infection, and Herpes. It may be used alone or in combination with Valacyclovir, as seen in clinical trials such as NCT02983019.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Kagocel |
|---|---|
| Sponsor | Nearmedic Plus LLC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
- Treatment of Influenza and ARVI in Children by Kagocel ®
- Kagocel® for the Prevention of ARVI and Influenza in Young People
- Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers
- Treatment of Influenza in Routine Clinical Practice
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kagocel CI brief — competitive landscape report
- Kagocel updates RSS · CI watch RSS
- Nearmedic Plus LLC portfolio CI
Frequently asked questions about Kagocel
What is Kagocel?
Who makes Kagocel?
What development phase is Kagocel in?
Related
- Manufacturer: Nearmedic Plus LLC — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing